vs
HERITAGE FINANCIAL CORP（HFWA）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
HERITAGE FINANCIAL CORP的季度营收约是RECURSION PHARMACEUTICALS, INC.的1.9倍（$66.3M vs $35.5M），HERITAGE FINANCIAL CORP净利率更高（33.5% vs -304.2%，领先337.8%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 16.3%），HERITAGE FINANCIAL CORP自由现金流更多（$85.7M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 16.8%）
总部位于美国华盛顿州的区域性金融控股公司，面向太平洋西北地区的当地社群提供服务，核心业务涵盖商业与零售银行服务，包含存款产品、中小企业贷款、住房抵押贷款、个人信贷及财富管理解决方案，核心客群为中小微企业及个人客户。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
HFWA vs RXRX — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $66.3M | $35.5M |
| 净利润 | $22.2M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | 38.7% | -304.8% |
| 净利率 | 33.5% | -304.2% |
| 营收同比 | 16.3% | 681.7% |
| 净利润同比 | 86.4% | 39.6% |
| 每股收益（稀释后） | $0.65 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $66.3M | $35.5M | ||
| Q3 25 | $65.7M | $5.2M | ||
| Q2 25 | $56.5M | $19.2M | ||
| Q1 25 | $57.6M | $14.7M | ||
| Q4 24 | $57.1M | $4.5M | ||
| Q3 24 | $54.8M | $26.1M | ||
| Q2 24 | $56.4M | $14.4M | ||
| Q1 24 | $48.6M | $13.8M |
| Q4 25 | $22.2M | $-108.1M | ||
| Q3 25 | $19.2M | $-162.3M | ||
| Q2 25 | $12.2M | $-171.9M | ||
| Q1 25 | $13.9M | $-202.5M | ||
| Q4 24 | $11.9M | $-178.9M | ||
| Q3 24 | $11.4M | $-95.8M | ||
| Q2 24 | $14.2M | $-97.5M | ||
| Q1 24 | $5.7M | $-91.4M |
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
| Q4 25 | 38.7% | -304.8% | ||
| Q3 25 | 34.0% | -3327.6% | ||
| Q2 25 | 25.6% | -916.8% | ||
| Q1 25 | 28.1% | -1297.9% | ||
| Q4 24 | 28.6% | -4042.4% | ||
| Q3 24 | 23.8% | -377.1% | ||
| Q2 24 | 28.4% | -697.4% | ||
| Q1 24 | 14.1% | -698.4% |
| Q4 25 | 33.5% | -304.2% | ||
| Q3 25 | 29.2% | -3135.3% | ||
| Q2 25 | 21.6% | -894.2% | ||
| Q1 25 | 24.2% | -1373.3% | ||
| Q4 24 | 20.9% | -3935.5% | ||
| Q3 24 | 20.8% | -367.5% | ||
| Q2 24 | 25.1% | -676.6% | ||
| Q1 24 | 11.8% | -662.4% |
| Q4 25 | $0.65 | $-0.17 | ||
| Q3 25 | $0.55 | $-0.36 | ||
| Q2 25 | $0.36 | $-0.41 | ||
| Q1 25 | $0.40 | $-0.50 | ||
| Q4 24 | $0.34 | $-0.56 | ||
| Q3 24 | $0.33 | $-0.34 | ||
| Q2 24 | $0.41 | $-0.40 | ||
| Q1 24 | $0.16 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $233.1M | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $921.5M | $1.1B |
| 总资产 | $7.0B | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
| Q4 25 | $233.1M | $743.3M | ||
| Q3 25 | $245.5M | $659.8M | ||
| Q2 25 | $254.1M | $525.1M | ||
| Q1 25 | $248.7M | $500.5M | ||
| Q4 24 | $117.1M | $594.4M | ||
| Q3 24 | $175.6M | $427.6M | ||
| Q2 24 | $113.8M | $474.3M | ||
| Q1 24 | $189.6M | $296.3M |
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
| Q4 25 | $921.5M | $1.1B | ||
| Q3 25 | $904.1M | $1.0B | ||
| Q2 25 | $888.2M | $919.1M | ||
| Q1 25 | $881.5M | $933.9M | ||
| Q4 24 | $863.5M | $1.0B | ||
| Q3 24 | $874.5M | $524.6M | ||
| Q2 24 | $850.5M | $584.4M | ||
| Q1 24 | $847.6M | $401.2M |
| Q4 25 | $7.0B | $1.5B | ||
| Q3 25 | $7.0B | $1.4B | ||
| Q2 25 | $7.1B | $1.3B | ||
| Q1 25 | $7.1B | $1.3B | ||
| Q4 24 | $7.1B | $1.4B | ||
| Q3 24 | $7.2B | $726.5M | ||
| Q2 24 | $7.1B | $775.9M | ||
| Q1 24 | $7.1B | $557.8M |
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $94.8M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $85.7M | $-47.3M |
| 自由现金流率自由现金流/营收 | 129.1% | -133.1% |
| 资本支出强度资本支出/营收 | 13.8% | 3.5% |
| 现金转化率经营现金流/净利润 | 4.26× | — |
| 过去12个月自由现金流最近4个季度 | $149.0M | $-378.3M |
8季度趋势，按日历期对齐
| Q4 25 | $94.8M | $-46.1M | ||
| Q3 25 | $25.1M | $-117.4M | ||
| Q2 25 | $22.5M | $-76.4M | ||
| Q1 25 | $19.3M | $-132.0M | ||
| Q4 24 | $64.5M | $-115.4M | ||
| Q3 24 | $24.2M | $-59.2M | ||
| Q2 24 | $6.8M | $-82.2M | ||
| Q1 24 | $12.9M | $-102.3M |
| Q4 25 | $85.7M | $-47.3M | ||
| Q3 25 | $24.4M | $-117.6M | ||
| Q2 25 | $20.9M | $-79.6M | ||
| Q1 25 | $18.1M | $-133.8M | ||
| Q4 24 | $61.0M | $-116.7M | ||
| Q3 24 | $23.2M | $-63.8M | ||
| Q2 24 | $6.0M | $-83.4M | ||
| Q1 24 | $12.0M | $-109.0M |
| Q4 25 | 129.1% | -133.1% | ||
| Q3 25 | 37.1% | -2272.5% | ||
| Q2 25 | 37.0% | -413.9% | ||
| Q1 25 | 31.4% | -907.4% | ||
| Q4 24 | 107.0% | -2567.7% | ||
| Q3 24 | 42.4% | -244.6% | ||
| Q2 24 | 10.6% | -578.5% | ||
| Q1 24 | 24.7% | -789.9% |
| Q4 25 | 13.8% | 3.5% | ||
| Q3 25 | 1.0% | 4.7% | ||
| Q2 25 | 2.8% | 16.4% | ||
| Q1 25 | 2.0% | 12.4% | ||
| Q4 24 | 6.1% | 28.6% | ||
| Q3 24 | 1.7% | 17.5% | ||
| Q2 24 | 1.5% | 8.2% | ||
| Q1 24 | 1.8% | 48.2% |
| Q4 25 | 4.26× | — | ||
| Q3 25 | 1.31× | — | ||
| Q2 25 | 1.84× | — | ||
| Q1 25 | 1.38× | — | ||
| Q4 24 | 5.41× | — | ||
| Q3 24 | 2.12× | — | ||
| Q2 24 | 0.48× | — | ||
| Q1 24 | 2.24× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
